SG11201506937RA - Improved preparation method for high-yield production of physiologically active polypeptide conjugate - Google Patents

Improved preparation method for high-yield production of physiologically active polypeptide conjugate

Info

Publication number
SG11201506937RA
SG11201506937RA SG11201506937RA SG11201506937RA SG11201506937RA SG 11201506937R A SG11201506937R A SG 11201506937RA SG 11201506937R A SG11201506937R A SG 11201506937RA SG 11201506937R A SG11201506937R A SG 11201506937RA SG 11201506937R A SG11201506937R A SG 11201506937RA
Authority
SG
Singapore
Prior art keywords
physiologically active
active polypeptide
polypeptide conjugate
yield production
improved preparation
Prior art date
Application number
SG11201506937RA
Inventor
Myung Hyun Jang
Min Young Kim
Dae Jin Kim
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SG11201506937RA publication Critical patent/SG11201506937RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201506937RA 2013-03-05 2014-03-05 Improved preparation method for high-yield production of physiologically active polypeptide conjugate SG11201506937RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130023602 2013-03-05
PCT/KR2014/001818 WO2014137161A1 (en) 2013-03-05 2014-03-05 Improved preparation method for high-yield production of physiologically active polypeptide conjugate

Publications (1)

Publication Number Publication Date
SG11201506937RA true SG11201506937RA (en) 2015-10-29

Family

ID=51491612

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506937RA SG11201506937RA (en) 2013-03-05 2014-03-05 Improved preparation method for high-yield production of physiologically active polypeptide conjugate

Country Status (23)

Country Link
US (1) US10660940B2 (en)
EP (1) EP2966083B1 (en)
JP (1) JP6374412B2 (en)
KR (1) KR102136336B1 (en)
CN (2) CN105143255B (en)
AR (1) AR094987A1 (en)
AU (1) AU2014226741B2 (en)
BR (1) BR112015021764B1 (en)
CA (1) CA2903365C (en)
ES (1) ES2743612T3 (en)
HK (1) HK1217717A1 (en)
IL (1) IL240869B (en)
MX (1) MX367817B (en)
MY (1) MY186423A (en)
NZ (1) NZ712948A (en)
PH (1) PH12015501952B1 (en)
PT (1) PT2966083T (en)
RU (1) RU2677796C9 (en)
SA (1) SA515360980B1 (en)
SG (1) SG11201506937RA (en)
TW (1) TWI647240B (en)
WO (1) WO2014137161A1 (en)
ZA (1) ZA201507312B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081755A1 (en) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd FORMULATION OF PROLONGED ACTION OF THE FOLICULES STIMULATING HORMONE WHERE AN IMMUNOGLOBULIN FRAGMENT, PREPARATION METHOD AND METHOD TO TREAT A SUBJECT SUFFERING A REPRODUCTIVE DISORDER ARE USED
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
AR090281A1 (en) 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
WO2019066603A1 (en) * 2017-09-29 2019-04-04 한미약품 주식회사 Persistent protein conjugate with improved efficiency
US11717577B2 (en) 2019-07-18 2023-08-08 Hanmi Pharm. Co., Ltd. Method for preparing long-acting drug conjugate through preparation of intermediate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CN1767857A (en) * 2003-02-26 2006-05-03 尼克塔治疗亚拉巴马公司 Polymer-factor VIII moiety conjugates
KR101135244B1 (en) * 2007-11-29 2012-04-24 한미사이언스 주식회사 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
CN103212084B (en) 2003-11-13 2018-07-13 韩美科学株式会社 Contain pharmaceutical composition of the immunoglobulin FC region as carrier
CU23556A1 (en) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST
KR20130116386A (en) * 2008-04-14 2013-10-23 할로자임, 아이엔씨 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
JP5563572B2 (en) * 2008-07-23 2014-07-30 ハンミ サイエンス カンパニー リミテッド Bioactive polypeptide drug conjugates using non-peptidic polymers with tri-terminal functional groups
WO2010078376A2 (en) * 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
AR081066A1 (en) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
KR101330868B1 (en) 2010-06-08 2013-11-18 한미사이언스 주식회사 Insulin derivative drug conjugate using an immunoglobulin fragment

Also Published As

Publication number Publication date
MY186423A (en) 2021-07-22
AR094987A1 (en) 2015-09-09
EP2966083A1 (en) 2016-01-13
PH12015501952A1 (en) 2016-01-18
US10660940B2 (en) 2020-05-26
RU2677796C2 (en) 2019-01-21
AU2014226741A1 (en) 2015-10-29
CA2903365C (en) 2022-06-07
RU2015139510A (en) 2017-04-07
RU2677796C9 (en) 2019-03-15
JP2016514110A (en) 2016-05-19
BR112015021764B1 (en) 2022-07-19
US20160008484A1 (en) 2016-01-14
ZA201507312B (en) 2017-04-26
CN105143255B (en) 2019-10-08
JP6374412B2 (en) 2018-08-15
IL240869A0 (en) 2015-10-29
IL240869B (en) 2019-06-30
PT2966083T (en) 2019-09-17
CN105143255A (en) 2015-12-09
CN110590903A (en) 2019-12-20
HK1217717A1 (en) 2017-01-20
EP2966083A9 (en) 2016-06-01
AU2014226741B2 (en) 2018-10-18
PH12015501952B1 (en) 2016-01-18
SA515360980B1 (en) 2019-02-14
BR112015021764A2 (en) 2017-08-29
CA2903365A1 (en) 2014-09-12
TW201514207A (en) 2015-04-16
TWI647240B (en) 2019-01-11
EP2966083B1 (en) 2019-06-05
NZ712948A (en) 2021-01-29
WO2014137161A1 (en) 2014-09-12
KR20140109342A (en) 2014-09-15
EP2966083A4 (en) 2016-10-26
KR102136336B1 (en) 2020-07-22
MX367817B (en) 2019-09-06
ES2743612T3 (en) 2020-02-20
MX2015011668A (en) 2015-12-16

Similar Documents

Publication Publication Date Title
GB2518547B (en) Method for the preparation of high purity lignin
HK1200466A1 (en) Method for the preparation of surfactant peptides
HK1201858A1 (en) An improved process for preparation of physiologically active polypeptide complex
ZA201403189B (en) Method for preparing physiologically active polypeptide complex
HK1217717A1 (en) Improved preparation method for high-yield production of physiologically active polypeptide conjugate
SI3027634T1 (en) Process for preparation of tulathromycin
HK1209790A1 (en) Method of producing recombinant iduronate-2-sulfatase -2-
HK1198584A1 (en) Process for the preparation of travoprost
EP2834188A4 (en) Formation of conjugated protein by electrospinning
IL236450A (en) Process for the preparation of 5-fluoro-1h-pyrazoles
HK1210225A1 (en) Procedure for the production of tiacumicin
EP3325496C0 (en) Method of preparing physiologically active polypeptide conjugate
PL2964607T3 (en) Process for the preparation of halogen-n, n-dimethylbenzylamines
HK1211789A1 (en) Plants for production of therapeutic proteins
EP3027739A4 (en) Modified cells for production of blood cells
EP2976326A4 (en) Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
PL2883461T3 (en) Process for producing active follistatin
EP2817305A4 (en) An improved process for the preparation of aprepitant
HK1218295A1 (en) Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from trifluoroacetylacetic acid 6--3-
IL229669A0 (en) Process for preparation of 1,2,3 -triazole-4-carboxamides
EP3049402A4 (en) Process for preparation of alogliptin
EP2906536A4 (en) An improved process for preparation of perindopril intermediate
TH1501004995A (en) Improved preparation method for high yield production of polypeptides. Pharmacologically active conjugates
GB201315268D0 (en) Process for preparation of blood group antigen derivatives
PL399603A1 (en) Process for the preparation of 3ß, 15α-dihydroxy-5α-androst-17-one